Revenue

12 Months Ended

Mar. 31, 2021

Revenue from Contract with Customer [Abstract]

Revenue

Revenue

Revenue Recognition

The following table presents DXC's revenues disaggregated by geography, based on the location of incorporation of the DXC entity providing the related goods or services:

	Twelve Months Ended
(in millions)	March 31, 2021		March 31, 2020		March 31, 2019
United States	$	5,983	$	7,225	$	7,677
U.K.	2,413		2,776		3,175
Other Europe	5,129		5,121		5,294
Australia	1,529		1,487		1,582
Other International	2,675		2,968		3,025
Total Revenues	$	17,729	$	19,577	$	20,753

The revenue by geography pertains to both of the Company’s reportable segments. Refer to Note 20 - "Segment and Geographic Information" for the Company’s segment disclosures.

Remaining Performance Obligations

Remaining performance obligations represent the aggregate amount of the transaction price in contracts allocated to performance obligations not delivered, or partially undelivered, as of the end of the reporting period. Remaining performance obligation estimates are subject to change and are affected by several factors, including terminations, changes in the scope of contracts, periodic revalidations, adjustments for revenue that has not materialized and adjustments for currency. As of March 31, 2021, approximately $23 billion of revenue is expected to be recognized from remaining performance obligations. The Company expects to recognize revenue on approximately 39% of these remaining performance obligations in fiscal 2022, with the remainder of the balance recognized thereafter.

Contract Balances

The following table provides information about the balances of the Company's trade receivables and contract assets and contract liabilities:

	As of
(in millions)	March 31, 2021		March 31, 2020
Trade receivables, net	$	2,871	$	3,059
Contract assets	$	351	$	454
Contract liabilities	$	1,701	$	1,756

Change in contract liabilities were as follows:

(in millions)	Twelve Months Ended March 31, 2021		Twelve Months Ended March 31, 2020
Balance, beginning of period	$	1,756	$	1,886
Deferred revenue	2,933		2,910
Recognition of deferred revenue	(2,922)		(2,925)
Currency translation adjustment	128		(48)
Other(1)	(194)		(67)
Balance, end of period	$	1,701	$	1,756

(1) Other included contract liabilities of $52 million related to the divested HHS business discussed in Note 3 - "Divestitures" and $62 million related to HPS business and other insignificant businesses reclassified to assets held for sale discussed in Note 4 - "Assets Held for Sale".

The following tables provides information about the Company’s capitalized costs to obtain and fulfill a contract:

	As of
(in millions)	March 31, 2021		March 31, 2020
Capitalized sales commission costs(1)	$	256	$	262
Transition and transformation contract costs, net(2)	$	888	$	874

Amortization expense of capitalized sales commission and transition and transformation contract costs were as follows:

	Fiscal Years Ended
(in millions)	March 31, 2021		March 31, 2020		March 31, 2019
Capitalized sales commission costs amortization(1)	$	70	$	72	$	62
Transition and transformation contract cost amortization(2)	$	264	$	280	$	258

(1)Capitalized sales commission costs are included within other assets in the accompanying balance sheets and amortization expense related to the capitalized sales commission assets are included in selling, general, and administrative expenses in the accompanying statements of operations.

(2)Transition and transformation contract costs, net reflect the Company’s setup costs incurred upon initiation of an outsourcing contract that are classified as other assets in the accompanying balance sheets and amortization expense are included within depreciation and amortization in the accompanying statements of operations.